Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ("statins") in familial combined hyperlipidemia

The American Journal of Cardiology
G SchonfeldN Elias

Abstract

Familial combined hyperlipidemia (FCHL) is a heterogeneous genetic disorder characterized by multiple lipoprotein phenotypes. The genetic defect is unknown, although linkage to the region of the apolipoprotein (apo) A-I-apoC-III-apo A-IV gene cluster on chromosome 11 has been suggested. The metabolic abnormality in many affected individuals is overproduction of apoB-containing lipoproteins causing elevated levels of plasma cholesterol, triglycerides, or both. Low levels of high-density lipoprotein (HDL) cholesterol and an abundance of dense low-density lipoprotein (LDL) particles are other features contributing to the high association of this disorder with premature coronary artery disease. Many affected individuals need drug therapy to lower their lipid levels. The hepatic 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or "statins," offer a potent therapeutic option in patients with FCHL. These drugs significantly decrease levels of total cholesterol, LDL cholesterol, and apoB, although their effects on HDL cholesterol and triglycerides are limited. The mechanisms by which statins exert their beneficial effects in patients with FCHL remain controversial. We studied 7 patients with FCHL and 5 genetically ...Continue Reading

References

Jan 1, 1977·Annual Review of Biochemistry·J L Goldstein, M S Brown
Oct 1, 1992·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·S P BabirakJ D Brunzell
Jul 1, 1990·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·M A AustinR M Krauss
Mar 15, 1989·The Biochemical Journal·B KhanM Heimberg
Jul 1, 1988·Annals of Internal Medicine·C EastS M Grundy
Jul 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·D W BilheimerJ L Goldstein
Feb 1, 1980·European Journal of Clinical Investigation·A ChaitJ D Brunzell
Oct 1, 1994·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·G FranceschiniC R Sirtori
Jan 1, 1994·European Journal of Clinical Pharmacology·S ZambonG Crepaldi
Jan 1, 1997·The American Journal of Cardiology·M H DavidsonJ A Tobert

❮ Previous
Next ❯

Citations

Jan 12, 2001·The American Journal of Cardiology·M MillerJ D Otvos
Jun 22, 1999·Clinical Cardiology·D B Hunninghake
Jan 20, 2009·Heart & Lung : the Journal of Critical Care·Xingang ZhangYingxian Sun
Sep 9, 2000·Arteriosclerosis, Thrombosis, and Vascular Biology·C W RittershausU S Ryan
May 18, 1999·Current Opinion in Lipidology·B E AouizeratA J Lusis
Mar 13, 1999·Current Opinion in Lipidology·A Ogunko, M Evans
Apr 4, 1998·The American Journal of Cardiology·H N Ginsberg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.